RxDoctor Payments DataLook up a doctor →

Mehran Moussavian, DO

Interventional Cardiology · Chula Vista, CANPI 1689788234

Payments from drug & device makers

$1,559,340in general payments, 2019–2025

Across 1,082 payments — averaging $1441.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$751K
  • Boston Scientific$512K
  • Recor Medical Inc$141K
  • Johnson & Johnson$99K
  • Biotronik Inc.$12K
  • Heartflow, Inc.$12K
  • plus $32K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC32$751,368
Boston Scientific169$512,447
Recor Medical Inc3$140,705
Johnson & Johnson171$99,059
Biotronik Inc.76$12,416
Heartflow, Inc.12$11,657
Abbott224$10,781
Pfizer67$6,342
Edwards Lifesciences34$3,429
Medtronic(2 entities)44$2,223
Shockwave Medical, Inc15$1,231
AOP Health US, LLC2$1,075
AstraZeneca25$764
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)25$710
Canon Medical Systems USA, Inc.9$668
Impulse Dynamics (USA) Inc.10$624
Amgen27$560
Astellas Pharma US Inc14$506
Philips North America LLC3$271
Boehringer Ingelheim9$177
Abiomed4$157
Sanofi-aventis U.S. LLC9$156
Cvrx, Inc.4$127
Esperion Therapeutics, Inc.7$121
Actelion Pharmaceuticals US, Inc.17$116
Biosense Webster, Inc.2$114
Acera Surgical, Inc.1$107
Amarin Pharma, Inc.5$104
ZOLL Circulation Inc1$98
Merck4$81
E.r. Squibb & Sons, L.L.C.5$79
Regeneron Healthcare Solutions, Inc.4$73
Novo Nordisk4$70
Biocompatibles, Inc.3$54
Inari Medical, Inc.2$52
Inspire Medical Systems, Inc.1$49
Kestra Medical Technology Services, Inc.1$44
Cardiovascular Systems Inc.3$43
Gilead2$42
Cardiva Medical, Inc.2$40
Angiodynamics, Inc.1$40
Bard Peripheral Vascular, Inc.3$40
Baxter Healthcare2$38
Daiichi Sankyo Inc.2$38
Atricure, Inc.2$37
Saranas, Inc.1$33
Bardy Diagnostics, Inc.2$29
Arbor Pharmaceuticals, Inc.1$29
Itamar Medical Inc1$28
Organogenesis Inc.1$27
Portola Pharmaceuticals, LLC1$27
Endotronix, Inc.1$26
Novartis2$26
Bayer1$25
Cardinal Health 200 LLC1$23
United Therapeutics Corporation1$22
Cordis US CORP.1$19
Tactile Systems Technology Inc1$19
Chiesi USA, Inc.1$17
Curonix LLC1$16

How this compares

$1,559,340 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California →

Medicare billing

Part B allowed, 2024
$4,331,311
Medicare patients
3,397
Services billed
15,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional cardiology in Chula Vista

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →